# Combination Immunotherapy in Colorectal Cancer

> **NCT05571293** · PHASE2 · SUSPENDED · sponsor: **Weill Medical College of Cornell University** · enrollment: 36 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Botensilimab
- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT05571293
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-03-17
- **Primary completion:** 2025-11
- **Final completion:** 2026-06
- **Target enrollment:** 36 (ESTIMATED)
- **Why stopped:** Study is temporarily paused to review safety data.
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05571293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05571293, "Combination Immunotherapy in Colorectal Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05571293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*